PULMONARY CLINICAL TRIALS

The following clinical trials are either active and enrolling, upcoming or pending.  Contact information is also listed for patients interested in enrolling.

Titania

A Phase III, Multicenter, Randomized, Double – blind, Chronic –dosing, Parallel –group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations.  Click here for inclusion/exclusion criteria.

Principal Investigator:  Huimin Wu, MD
Core Clinical Research Staff:
Juvaria Anjum, RN
Brittany Karfonta

Pillar

A 52-week, randomized, double-blind, double-dummy, placebo- and active- controlled (Roflumilast, Daliresp® 500µg), parallel group, study to evaluate the efficacy and safety of two doses of CHF6001 DPI add-on to maintenance triple therapy in subjects with Chronic Obstructive Pulmonary Disease (COPD) and chronic bronchitis.  Click here for inclusion/exclusion criteria.

Principal Investigator:  Huimin Wu, MD
Core Clinical Research Staff:
Juvaria Anjum, RN
Brittany Karfonta

ATYR 1923 C 005

Randomized, double-blind, placebo-controlled Proof-of-Conept (PoC) study to evaluate the efficacy, safety, and tolerability of efzofitimod in patients with Systemic Sclerosis (SSc)-related interstitial Lung Disease (ILD) (SSc-ILD).  Click here for inclusion/exclusion criteria

Principal Investigator:  Jad Kebbe, MD
Core Clinical Research Staff:
Lauren Sinko, RN, BSN
Maria Mason, RN, BSN

Genentech GB44496

A two-cohort, phase II, multicenter randomized, double-blind, parallel-group, placebo-controlled study evaluating the efficacy and safety of Vixarelimab compared with placebo in patients with idiopathic pulmonary fibrosis and in patients with systemic sclerosis-associated interstitial lung disease.  Click here for inclusion/exclusion criteria

Principal Investigator:  Jad Kebbe, MD
Core Clinical Research Staff:
Lauren Sinko, RN, BSN
Maria Mason, RN, BSN

INSO18-055-003 (Insilico)

A phase 2a, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics, and efficay of INSO18-066 administered orally to subjects with Idiopathic Pulmonary Fibrosis (IPF).  

Principal Investigator:  Jad Kebbe, MD
Core Clinical Research Staff:
Lauren Sinko, RN, BSN
Maria Mason, RN, BSN

BMS IM026068

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis.

Principal Investigator:  Jad Kebbe, MD
Core Clinical Research Staff:
Lauren Sinko, RN, BSN
Maria Mason, RN, BSN

MTX-463-I201

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-463 in Participants with Idiopathic Pulmonary Fibrosis (IPF)

Principal Investigator:  Jad Kebbe, MD
Core Clinical Research Staff:
Lauren Sinko, RN, BSN
Maria Mason, RN, BSN

BMS IM0271015

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis

Principal Investigator:  Jad Kebbe, MD
Core Clinical Research Staff:
Lauren Sinko, RN, BSN
Maria Mason, RN, BSN

IPF-PRO

Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) and Interstitial Lung Disease Prospective Outcomes (ILD-PRO) Registry

Principal Investigator:  Jad Kebbe, MD
Core Clinical Research Staff:
Lauren Sinko, RN, BSN
Maria Mason, RN, BSN

BI 1490-0004

A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough

Principal Investigator:  Jad Kebbe, MD
Core Clinical Research Staff:
Lauren Sinko, RN, BSN
Maria Mason, RN, BSN

TP-CA-008 (MOMENTOUS)

Multi-site study of the clinical impact of an AI-assisted approach to referring patients with interstitial lung disease for diagnostic evaluation of pulmonary hypertension

Principal Investigator:  Jad Kebbe, MD
Core Clinical Research Staff:
Lauren Sinko, RN, BSN
Maria Mason, RN, BSN

DOMPE REP01222 (RESPIRATIO)

A phase II, proof-of-concept, randomized, double-blinded, placebo controlled, multicenter study to assess efficacy of Reparixin ass add-on therapy to standard of care in adult patients with ARDS (Acute Repiratory Distress Syndrome.  Click here for inclusions/exclusions criteria

Principal Investigator:  Tony Abdo, MD
Core Clinical Research Staff:
Lauren Sinko, RN, BSN
Maria Mason, RN, BSN

Biotest 996 ESsCAPE

A randomized, placebo-controlled, double-blind, multicenter, phase III trial to asess the efficacy and safety of Trimodulin (BT588) in adult hospitalized subjects with severe community-acquired pneumonia (sCAP).  Click here for inclusion/exclusion criteria

Principal Investigator:  Houssein Youness, MD
Core Clinical Research Staff:
Lauren Sinko, RN, BSN
Maria Mason, RN, BSN

VasoActive Therapy

To evaluate the impact of the vasoactive therapy upon patients with sepsis by following routinely monitored parameters of inflammation and organ failures scores to evaluate vasoactive therapy's efficacy in mitigating the impact of sepsis on the human body.  (This study is pending.)

Principal Investigator:  Brent Brown, MD
Core Clinical Research Staff:
Lauren Sinko, RN, BSN
Maria Mason, RN, BSN